ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: However, targeting BCR-ABL kinase activity alone may not be sufficient for the management of CML, as downstream pathways of BCR-ABL can be activated independently of BCR-ABL kinase activity [23], thereby leading to imatinib resistance.